Big Phar­ma back­ers jump on board 'Treg' car­tog­ra­pher's lead round with up to six can­di­dates in the pipe

Among the wealth of emerg­ing tar­gets in on­col­o­gy, im­mune sys­tem sup­press­ing reg­u­la­to­ry T cells — bet­ter known as “Tregs” — have earned some big-name in­ter­est in re­cent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER